[Current and future therapeutic options for COVID-19].
In: Nederlands tijdschrift voor geneeskunde, Jg. 166 (2022-07-21)
academicJournal
Zugriff:
The anti-inflammatory agents dexamethasone (corticosteroid), and tocilizumab and sarilumab (IL6-inhibitors) are effective in the treatment of late COVID-19. Other anti-inflammatory agents, like anakinra (IL1-inhibitor), baricitinib and tofacitinib (JAK-inhibitors) and lenzilumab (GM-CSF-inhibitor) have also shown positive results in late COVID-19. For the treatment of early COVID-19, the inhalation corticosteroid budesonide is regarded as an off-label treatment option. Virus-inhibitors, like remdesivir, molnupiravir and nirmatrelvir/ritonavir decrease the risk of hospitalization and the development of severe COVID-19 by patients with early symptoms. Monoclonal antibodies have shown limited or no efficacy against the omicron-variant of SARS-CoV-2. Fluvoxamine, l-arginine, AT-527 and ensovibep are considered as potential promising new therapies for the treatment of early COVID-19.
Titel: |
[Current and future therapeutic options for COVID-19].
|
---|---|
Autor/in / Beteiligte Person: | Dankers, M ; Nelissen-Vrancken, HMJMG ; Berger, MY ; Bonten, MJM ; van Gerven JMA ; Kunst, PWA ; Muller, M ; Olde Rikkert, MGM ; Rosendaal, FR |
Zeitschrift: | Nederlands tijdschrift voor geneeskunde, Jg. 166 (2022-07-21) |
Veröffentlichung: | 2017?-: Amsterdam : Vereniging NTvG ; <i>Original Publication</i>: Houten : Bohn Stafleu van Loghum, 2022 |
Medientyp: | academicJournal |
ISSN: | 1876-8784 (electronic) |
Schlagwort: |
|
Sonstiges: |
|